A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

Completed · Phase 2 · Has a placebo group

Conditions studied: Neovascular Age-related Macular Degeneration

In brief

This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).

Key facts

Study ID
NCT04331730
Run by
Alkahest, Inc.
People needed
107
Starts
2020-01-28
Expected to finish
2021-09-16
Last updated by the study team
2022-10-26

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.